Printer Friendly

Benitec Limited (ASX:BLT) Received Key Patent Notice of Intent To Re-Issue In the USA.

Melbourne, Australia, Nov 8, 2010 - (ABN Newswire) - Benitec Limited (ASX:BLT) (PINK:BNIKF), the , the leading company in expressed gene silencing for human therapeutics, announced today that the United States Patent and Trademark Office (USPTO) has issued an official Notice of Intent to Issue an Ex Parte Re-examination Certificate for US Patent 6,573,099 ("the '099 Graham Patent"), the wide-ranging platform technology patent covering the use of expressed RNAi in human therapeutic applications.

This Notice formally closes the long-running re-examination proceedings on this patent. The Ex Parte Re-examination Certificate will be issued shortly.

Benitec's CEO, Dr Peter French, welcomed the Notice. "The long re-examination process reflects the importance of this patent in the global field of gene silencing using RNA interference. This Notice, and other previously announced patent developments, clear the way for us to leverage our dominant patent estate globally in expressed RNA interference," he said.

"We are continuing to advance a broad pipeline of expressed RNAi-based therapeutic programs in oncology and infectious disease with particular focus on hepatitis B, lung cancer and cancer-associated neuropathic pain," Dr French added.

Benitec has exclusive rights to key claims in expressed RNAi for humans in most major jurisdictions including the US, the UK, Japan and China.

Australia's Commonwealth Scientific and Industrial Research Organisation (CSIRO), which has exclusively licensed the patent to Benitec for human therapeutics, also welcomed the Notice. "CSIRO is very pleased to see that this important patent will be reissued so that the potential therapeutic benefits of this transformational technology can be realised," commented Ms Jan Bingley, General Manager, IP and Licensing - CSIRO Operations.

About Benitec Limited:

Benitec Limited (ASX:BLT) (PINK:BNIKF) is an Australian biotechnology company focused on licensing its extensive intellectual property portfolio and developing therapeutics to treat serious diseases using its proprietary ddRNAi technology. For additional information, please visit www.benitec.com.

Copyright 2009 ABN Newswire

Provided by Syndigate.info an Albawaba.com company
COPYRIGHT 2010 Al Bawaba (Middle East) Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:ABN Newswire
Geographic Code:8AUST
Date:Nov 8, 2010
Words:319
Previous Article:D'Aguilar Gold Limited (ASX:DGR) Advises That Navaho Gold Negotiates Sixth Nevada Gold Project.
Next Article:Pluton Resources Limited (ASX:PLV) Irvine Island Assay Results - Isthmus Region.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters